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Abstract
Background
Severe leptospirosis is frequently complicated by a hemorrhagic diathesis, of which the
pathogenesis is still largely unknown. Thrombocytopenia is common, but often not to the
degree that spontaneous bleeding is expected. We hypothesized that the hemorrhagic com-
plications are not only related to thrombocytopenia, but also to platelet dysfunction, and that
increased binding of von Willebrand factor (VWF) to platelets is involved in both platelet dys-
function and increased platelet clearance.
Methodology/Principal findings
A prospective study was carried out in Semarang, Indonesia, enrolling 33 hospitalized
patients with probable leptospirosis, of whom 15 developed clinical bleeding, and 25 healthy
controls. Platelet activation and reactivity were determined using flow cytometry by measur-
ing the expression of P-selectin and activation of the αIIbβ3 integrin by the binding of fibrino-
gen in unstimulated samples and after ex vivo stimulation by the platelet agonists
adenosine-diphosphate (ADP) and thrombin-receptor activating peptide (TRAP). Platelet-
VWF binding, before and after VWF stimulation by ristocetin, as well as plasma levels of
VWF, active VWF, the VWF-inactivating enzyme ADAMTS13, thrombin-antithrombin com-
plexes (TAT) and P-selectin were also measured. Bleeding complications were graded
using the WHO bleeding scale. Our study revealed that platelet activation, with a secondary
platelet dysfunction, is a feature of patients with probable leptospirosis, especially in those
with bleeding manifestations. There was a significant inverse correlation of bleeding score
with TRAP-stimulated P-selectin and platelet-fibrinogen binding (R = -0.72, P = 0.003 and R
= -0.66, P = 0.01, respectively) but not with platelet count. Patients with bleeding also had a
significantly higher platelet-VWF binding. Platelet counts were inversely correlated with
platelet-VWF binding (R = -0.74; P = 0.0009. There were no correlations between platelet-
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VWF binding and the degree of platelet dysfunction, suggesting that increased platelet-
VWF binding does not directly interfere with the platelet αIIbβ3 signaling pathway in patients
with probable leptospirosis.
Conclusion/Significance
Platelet dysfunction is common in probable leptospirosis patients with manifest bleeding.
Increased VWF-platelet binding may contribute to the activation and clearance of platelets.
Author summary
Bleeding is a frequent complication of leptospirosis, a disease caused by the pathogenic
spirochaete Leptospira. Although thrombocytopenia is common, studies have shown that
it does not fully explain the bleeding events seen in these patients. We hypothesized that
platelet dysfunction plays a role in the development of bleeding complications. The pres-
ent study involved 33 hospitalized patients with probable leptospirosis and 25 healthy con-
trols. We report that circulating platelets from patients with severe, probable leptospirosis
were activated, but less reactive to ex vivo activation. The degree of this platelet dysfunc-
tion was associated with bleeding, in contrast to the degree of thrombocytopenia. Platelets
of leptospirosis patients also demonstrated increased binding with von Willebrand factor
(VWF), and a strong negative correlation with platelet count suggesting that this binding
is important for platelet clearance.
Introduction
Leptospirosis is a zoonotic disease of global importance caused by the pathogenic spirochaetes
of the genus Leptospira [1, 2]. A modeling exercise by the World Health Organization’s
(WHO’s) Leptospirosis Burden Epidemiology Group, estimated that 873,000 cases and 48,600
deaths occur worldwide each year [3]. The clinical manifestations of leptospirosis range from a
mild, self-limited febrile illness to a fulminant life-threatening illness with multi-organ failure
[1, 2]. Bleeding complications are common in severe leptospirosis, being reported in up to
60% of all hospitalized patients. Although the majority of bleeding events are mild, some
patients may develop severe gastrointestinal or pulmonary hemorrhage, the latter having an
alarmingly high mortality of>50% [4, 5].
The pathophysiological mechanisms responsible for bleeding remain incompletely under-
stood. Thrombocytopenia is frequently observed and is associated with poor outcome [6], but
its severity is not to the extent that spontaneous bleeding is expected [7]. Platelet dysfunction
might also contribute to bleeding. Measuring platelet function in thrombocytopenic condi-
tions is technically demanding as commonly used techniques such as light transmission aggre-
gometry are not useful [8]. To the best of our knowledge, no studies on platelet function in
leptospirosis have been performed.
Platelets are involved in primary hemostasis, wherein they aggregate and form a plug to seal
off vascular leakage. Platelet adhesion is initiated by the binding of GPIbα and GPVI receptors
on platelets to VWF on endothelial surface and collagen, respectively, of which both are
exposed from the subendothelium after vascular injury. Platelets are then activated, and adhe-
sion and aggregation is strengthened via the platelet αIIbβ3 receptor binding with fibrinogen
and von Willebrand factor (VWF).
Platelet dysfunction in patients with probable leptospirosis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005915 September 21, 2017 2 / 18
The binding of VWF to the glycoprotein (GP)-1b receptor on platelets is a well-known
platelet clearance mechanism [9]. VWF is a multimeric glycoprotein that predominantly origi-
nates from the endothelium. Its main function is the recruitment of platelets to sites of vascular
injury. Under normal conditions, most of the VWF circulates in non-platelet binding form.
VWF may however undergo a conformational change to a more active, platelet-binding form
facilitating platelet aggregation [10]. An increase in this so-called ‘active’ VWF has been
described in a number of infectious and non-infectious diseases [11–13]. A deficiency in
ADAMTS13 (a disintegrin and metalloproteinase thrombospondin type 1 motif, member 13),
an enzyme that cleaves large VWF multimers into their inactive conformation, may also lead
to excessive intravascular platelet agglutination [14].
Von Willebrand disease type 2B is characterized by excessive VWF binding to platelets.
Recently, it was reported that this excessive binding not only leads to thrombocytopenia, but
also to thrombocytopathy via inhibition of the platelet αIIbβ3, an integrin that primarily medi-
ates platelet aggregation through binding of fibrinogen [15]. In addition, excessive platelet acti-
vation may also lead to exhausted and hence dysfunctional platelets [16]. We previously found
in patients with dengue hemorrhagic fever that circulating platelets were activated, but less
reactive to ex vivo stimulation with platelet agonists [17]. We hypothesized that similar platelet
changes also occur in other hemorrhagic infectious diseases, including in severe leptospirosis.
Specifically, we hypothesized that circulating platelets in severe leptospirosis are activated and
have bound more VWF and that both these processes contribute to thrombocytopenia and
platelet dysfunction, especially in those with bleeding complications. We therefore character-
ized VWF binding to platelets, platelet activation and platelet reactivity using flow cytometry
in adult Indonesian patients with probable leptospirosis and determined whether these param-
eters were related to bleeding complications. In addition, we determined the plasma levels of
VWF, active VWF, P-selectin, the plasma coagulation factor thrombin-antithrombin com-
plexes (TAT) and ADAMTS13 activity.
Methods
Ethics statement
The study was approved by the Ethics Committee of the Faculty of Medicine Diponegoro Uni-
versity and Dr Kariadi Hospital, Semarang, Indonesia. Upon participation, all participants
signed an informed consent form.
Study population
We carried out a prospective study at the Department of Internal Medicine of Dr. Kariadi Hos-
pital, Semarang, Indonesia, between December 2013-March 2014. We enrolled adult patients
admitted with a high clinical suspicion of leptospirosis using the case definition of the World
Health Organization South East Asia Regional Office supported by a positive result of Leptos-
pira IgM lateral flow (Pakar Biomedika, Indonesia), classifying them as probable leptospirosis
[18]. The Leptospira IgM lateral flow test had a reported sensitivity and specificity of 85.6%
and 96.2%, respectively [19], while another study by Goris et. al. reported a specificity of 95%
[20]. Clinical diagnosis of leptospirosis was confirmed in a single acute sample by microscopic
agglutination test (MAT) with a panel consisting of 31 serovars (28 pathogenic serovars: Aus-
tralis, Bratislava, Autumnalis, Rachmati, Ballum, Castellonis, Bataviae, Benjamini, Whitcombi,
Cynopteri, Grippotyphosa, Hebdomadis, Copenhageni, Hardjo, Icterohaemorrhagiae, Lai,
Naam, Coxi, Javanica, Panama, Pomona, Proechimys, Pyrogenes, Sarmin, Saxkoebing, Sejroe,
Shermani, Tarassovi; three non-pathogenic serovars: Andamana, Patoc and Semaranga). A
titre of1/320 on a single sample was considered positive. Additionally, dengue IgM/IgG
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serology was tested in all patients as part of the protocol in patients with clinical suspicion of
leptospirosis in the hospital where this study was performed, and patients with a positive den-
gue IgM were not enrolled. Healthy controls were all tested negative for rapid Leptospira IgM
lateral flow. All diagnostic tests were performed at the National Reference Laboratory for Lep-
tospira, Dr. Kariadi Hospital, Semarang, Indonesia. Patients and healthy controls were
included after written informed consent was obtained. Blood samples were obtained on inclu-
sion day (day 1) and upon follow up (day 4). The study is approved by the ethical committee of
the Faculty of Medicine Diponegoro University-Dr. Kariadi Hospital, Semarang, Indonesia.
Platelet activation and reactivity and platelet-von Willebrand factor
binding
Whole blood was collected from patients by using venipuncture from the antecubital vein into
citrate-anticoagulated tubes (3.2%; BD Vacutainer, Becton Dickinson). All samples were pro-
cessed within one hour after blood collection. Platelet activation and reactivity were deter-
mined by flow cytometry using a method previously described [21, 22]. In short, the platelet
membrane expression of P-selectin (CD62P) and platelet-fibrinogen binding, which corre-
spond with platelet degranulation and aggregation, were determined in unstimulated whole
blood and in whole blood stimulated 20 min with the platelet agonists adenosine-diphosphate
(ADP; 7.8 μM and 31.2 μM) or thrombin receptor-activating peptide (TRAP; 39 μM and
625 μM) diluted in HEPES-buffered saline. Saturating concentrations of the following mono-
clonal antibodies were used: PE-labeled anti-CD62P (Bio-Legend, San Diego, USA), FITC-
labeled anti-fibrinogen (DAKO Ltd., High Wycombe, UK), and PC7-labeled anti-CD61 (plate-
let identification marker; Beckman Coulter, France). Platelets were gated based on their for-
ward- and sideward-scatter (FSC/SSC) properties and positivity for CD61, which was defined
as a median fluorescence intensity (MFI) exceeding the MFI of the matched isotype control.
The binding of VWF to platelets was determined by adding whole blood sample to a mix-
ture of HEPES-buffered saline and saturating concentrations of FITC-labeled anti-von Willeb-
rand factor (Abcam, Cambridge, UK) and PC7-labeled anti-CD61, with or without the
addition of ristocetin (0,84 mg/ml and 1,5 mg/ml). After incubation for 20 minutes at room
temperature, a fixative solution (0.2% paraformaldehyde) was added and samples were ana-
lyzed with a BD FACS Canto II flow cytometer (Becton Dickinson, USA). Next, the MFI of
CD62P, fibrinogen and VWF on CD61-positive events were determined.
Plasma markers
Platelet-poor plasma was obtained from citrate-anticoagulated whole blood by centrifugation
(1500 g without brake, 15 min, 20ehyde) was added and thrombin-antithrombin (TAT) com-
plexes were subsequently measured with enzyme-linked immunosorbent assay (ELISA) as pre-
viously described [24]. Sheep anti-human thrombin (SAHT-AP, SAHT-HRP) antibodies were
purchased from Kordia/Affinity Biologicals, USA. Plasma VWF concentrations were deter-
mined with ELISA as described previously [23]. Active VWF was quantified by ELISA using a
nanobody (AU/VWFa-11) that recognizes the GPIb binding configuration of VWF, as
described previously [24]. We express the relative amount of VWF that circulates in its active,
platelet binding conformation by using the term VWF activation factor. VWF activation factor
of normal pooled plasma was referred to as 1. ADAMTS13 activity was quantified using the
fluorescence resonance energy transfer (FRETS) assay (Peptides International, Lexington,
USA), whereby the ADAMTS13 activity of normal pool plasma was set at 100%, and the values
obtained in study participant samples were expressed as percentage of normal pool plasma
[25].
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Statistical analysis
Differences in subject characteristics were compared with analysis of variance (ANOVA) with
posttests for comparing more than two groups, and with Mann-Whitney U-test or chi-square
test for comparing the two patient groups. Data are presented as median with interquartile
range (IQR) unless stated otherwise. Relationships between parameters were assessed with the
Spearman correlation coefficient. All analyses were performed with SPSS version 20 (SPSS,
Inc., Chicago, Illinois, USA). P values less than 0.05 were considered statistically significant.
Results
Patient characteristics
Thirty-three consecutive hospitalized patients with probable leptospirosis were enrolled
together with 25 healthy controls. Twelve (36%) of these patients had a positive result of the
MAT (titer>1/320). All patients were tested negative for dengue IgM, while 29 had a positive
dengue IgG (12 in the bleeders group and 17 in the non-bleeders group). Characteristics of
participants are presented in Table 1. Fifteen patients (46%) presented with or developed clini-
cal relevant bleeding manifestations during hospitalization. The most common were gastroin-
testinal (n = 10) and genitourinary (n = 8) bleeding events. The severity of bleeding events in
patients was graded using the WHO bleeding scale [26–28]. Ten out of 15 patients (67%) who
experienced clinical bleeding developed Grade 2 bleeding (i.e. epistaxis with a total duration of
all episodes in previous 24 hours of>30 minutes, grossly visible blood in urine, stool or eme-
sis), while 4 (27%) developed that of Grade 1 (i.e. epistaxis with a total duration in previous 24
hours of<30 minutes, microscopic hematuria and petechiae). There was one patient (7%)
with Grade 3 bleeding whose hematemesis and melena caused hemodynamic instability. One
Grade 1 (7%) and three (20%) Grade 2 patients died during hospitalization.
Median (IQR) platelet count was significantly lower in the group of bleeders compared
with the non-bleeders (105, 56-152x109/l vs. 123, 106–183 x109/l; P = 0.003). Five patients had
a platelet count lower than 50 x109/l (platelet counts of four bleeders: 12 x109/l, 17 x109/l, 30
x109/l, 30 x109/l; platelet count of one non-bleeder: 49 x109/l). Additionally, the hemoglobin
levels were lower in the bleeders group than the non-bleeders group (10.9, 9.4–13.2 gr/dl vs.
14.8, 13.9–16.5 gr/dl; P = 0.004), with six patients having hemoglobin levels below 10gr/dl
(hemoglobin levels of five bleeders: 8.2 gr/dl, 8.9 gr/dl, 9.1 gr/dl, 9.4 gr/dl, 9.8 gr/dl; hemoglo-
bin level of one non-bleeder: 9.5 gr/dl). Leukopenia is a common presentation of dengue.
However, none of the patients in our patient cohort had leukopenia at presentation, with a
median (interquartile range) of leukocyte of 14.5 x109/l (9.4 x109/l -17.4 x109/l).
Bleeding is associated with higher platelet activation and platelet
dysfunction
Fig 1A shows the fibrinogen binding to the activated αIIbβ3 receptor and expression of P-selec-
tin on platelets. Patients with bleeding had significantly higher platelet-fibrinogen binding
(MFI 2601, 1726–2938 vs. 1577, 1460–1752; P = 0.001) and P-selectin (MFI 1095, 798–1685 vs.
654, 575–1056; P = 0.002) in unstimulated blood samples than controls, suggesting increased
platelet activation. The non-bleeding patients also had significantly higher membrane P-selec-
tin expression compared to controls (MFI 1179, 910–1444; P = 0.003). Platelet reactivity was
assessed by ex vivo stimulation of whole blood with two concentrations of the platelet agonists
ADP or TRAP. In contrast to the findings in unstimulated samples, P-selectin expression and
fibrinogen binding in response to TRAP or ADP were lower in the bleeders compared with
Platelet dysfunction in patients with probable leptospirosis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005915 September 21, 2017 5 / 18
non-bleeders and controls, suggestive of platelet dysfunction. A reduction in platelet reactivity,
albeit to a lesser extent, was also found in the non-bleeders in response to TRAP.
Interestingly, whereas bleeding score was not associated with platelet count (Fig 1B), an
inverse relation was present for bleeding score with P-selectin expression and fibrinogen bind-
ing to ex vivo stimulation with TRAP (R = -0.72; P = 0.003 for P-selectin and R = -0.66;
P = 0.01 for fibrinogen; Fig 1B) and ADP (R = -0.41; P = 0.01 and R = -0.63; P = 0.03, respec-
tively; shown in S1 Fig).
The flow cytometric findings of platelet activation in bleeders were supported by measure-
ment of plasma concentrations of soluble P-selectin, which was significantly higher in bleeders
compared to both the non-bleeders and healthy controls. Plasma P-selectin in the non-bleed-
ers was comparable with that of the controls. Overall, leptospirosis patients also had signifi-
cantly higher plasma TAT concentrations, suggesting activation of the plasma coagulation
pathway, with the highest concentrations found in the bleeders (Fig 1C).
Comparing MAT-positive with MAT-negative patients, no differences were found in plate-
let activation status as well as platelet reactivity in the bleeders and non-bleeders (Fig 2). There
was a trend for lower platelet count in the MAT-positive group, with a median (IQR) of 135
x109/l (50 x109/l -180 x109/l), compared to the MAT-negative group (134 x109/l, 105 x109/l
Table 1.
All patients Bleeders Non-bleeders Reference values Controls P value
Numbers (%) 33 15 (46) 18 (54) 25
Male sex, n (%) 22 (67) 7 (46.7) 15 (83) 17 (68) 0.03
Age (years) 47 (36–53) 52 (38–59) 48 (40–52) 36 (32–50) 0.24
Bleeding events, n (%)
Oral, nasal, skin
Epistaxis 2 (6)
Petechiae 2 (6)
Gastrointestinal
Hematochezia 1 (3)
Hematemesis 5 (15)
Melena 4 (12)
Genitourinary
Microscopic hematuria 3 (9)
Gross hematuria 5 (15)
Days post-onset illness, n 8 (7–11) 7 (6–10) 7 (7–12) 0.12
MAT positive (%) 12 (36) 9 (60) 3 (17) 0.02
Hb (gr/dl) 13.3 (10.8–15) 10.9 (9.4–13.2) 14.8 (13.9–16.5) 12–15 0.004
Platelet count (x109/l) 114 (60–172) 105 (56–152) 123 (106–183) 150–300 0.003
Thrombocytopenia <150x109/l (%) 17 (52) 10 (67) 7 (39) 0.11
Thrombocytopenia <100x109/l (%) 9 (27) 7 (47) 2 (11) 0.03
Leukocyte count (x109/l) 14.5 (9.4–17.4)
Bilirubin (mg/dl) 1.6 (0.8–6.4) 2.0 (1.5–5.2) 1.3 (0.8–5.3) 0–1.0 0.28
AST (U/l) 89 (44–147) 84 (58–131) 95 (46–138) 15–35 0.72
ALT (U/l) 93 (63–160) 87 (62–131) 99 (79–193) 15–60 0.68
Urea (mg/dl) 47 (31–196) 64 (46–221) 36 (24–49) 15–39 0.06
Creatinine (mg/dl) 1.7 (1.1–4.6) 2.0 (1.4–5.1) 1.4 (1–2) 0.6–1.3 0.12
Numbers represent median (IQR) or number (%) of patients. P values represent difference between bleeders and non-bleeders (Mann-Whitney U-test or
chi-square test when appropriate). A P value <0.05 was considered statistically significant.
https://doi.org/10.1371/journal.pntd.0005915.t001
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Fig 1. Platelet activation and reactivity, plasma P-selectin and TAT complexes and the relationship between
bleeding and platelet number and reactivity. (A) Platelet-fibrinogen binding and the platelet membrane
expression of P-selectin (depicted as median fluorescence intensity (MFI) in arbitrary units) in unstimulated samples
and after stimulation with two concentrations of the platelet agonists thrombin receptor activating peptide (TRAP)
and adenosine diphosphate (ADP) in leptospirosis patients with bleeding (bleeders, n = 15) and without bleeding
(non-bleeders, n = 18) and in healthy controls (n = 25). Data depicted are medians with interquartile ranges (IQR). *
P<0.05, **P<0.005, ***P<0.001. (B) Correlations between the severity of bleeding, as measured using the WHO
bleeding scale, and platelet count, as well as TRAP-induced (625 μM) platelet P-selectin expression and platelet-
fibrinogen binding. Shown are the Spearman correlation coefficients. (C) Plasma concentration of soluble P-selectin
and thrombin-antithrombin (TAT) complex. The lines with error bars indicate medians with IQR.
https://doi.org/10.1371/journal.pntd.0005915.g001
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-244 x109/l; P = 0.09). Additionally, there were no statistically significant differences in the bili-
rubin, AST, ALT, ureum and creatinine levels between the MAT-positive and MAT-negative
patients. In further analyses, MAT-positive and MAT-negative cases were analyzed as a single
group of bleeders or non-bleeders.
Follow-up data at day four were available for 11 bleeders and 10 non-bleeders. Bleeders, but
not the non-bleeders, remained having a significantly reduced platelet reactivity in the follow-
up on day 4 compared to healthy controls (S2A Fig). Plasma P-selectin also remained signifi-
cantly increased at day 4 in bleeders (S2B Fig).
Platelet von-Willebrand factor binding was highest in bleeders
Binding of VWF to platelets is associated with platelet clearance, platelet activation and also
possibly platelet dysfunction [15, 29]. We determined platelet-VWF binding using flow cytom-
etry and measured plasma VWF levels, VWF activation factor and ADAMTS13 activity. Bleed-
ers had a significantly higher platelet-VWF binding (MFI 9069, 7470–10554) than non-
bleeders (MFI 6999, 4707–8250; P = 0.01) and healthy controls (MFI 7296, 6877–7867;
P = 0.002) (Fig 3A). Upon activation of VWF by ristocetin, the bleeding patients demonstrated
the highest increase in platelet-VWF binding (Fig 3B). These flow cytometric findings were
consistent with the observation that bleeders had the highest plasma VWF concentration
Fig 2. Platelet activation and reactivity in patient groups based on results of the microscopic agglutination test (MAT). Platelet-
fibrinogen binding and the platelet membrane expression of P-selectin (depicted as median fluorescence intensity (MFI) in arbitrary units) in
unstimulated samples and after stimulation with two concentrations of the platelet agonists thrombin receptor activating peptide (TRAP) and
adenosine diphosphate (ADP) in MAT-positive leptospirosis patients with bleeding (bleeders, n = 15; MAT(+), n = 9; MAT(-), n = 6) and without
bleeding (non-bleeders, n = 18; MAT(+), n = 3; MAT(-), n = 15) and in healthy controls (n = 25). Data depicted are medians with IQR. * P<0.05.
https://doi.org/10.1371/journal.pntd.0005915.g002
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Fig 3. Platelet-von Willebrand factor (VWF) binding, plasma VWF levels, VWF activation factor and ADAMTS13 activity levels. Platelet-
VWF binding (depicted as median fluorescence intensity (MFI) in arbitrary units) in unstimulated samples (A) and after ex vivo stimulation with two
concentrations of ristocetin (B). * P<0.05, ***P<0.001. (C-E) Plasma concentrations of VWF, VWF activation factor and ADAMTS13 activity.
Data are shown as medians with IQR. (F) Spearman correlation coefficient of VWF activation factor and platelet-VWF binding (left panel), as well
as plasma VWF and ADAMTS13 activity (right panel) of leptospirosis patients with and without bleeding.
https://doi.org/10.1371/journal.pntd.0005915.g003
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(Fig 3C) and that the VWF activation factor was about twofold higher in both the bleeding and
non-bleeding leptospirosis patients than in healthy controls, indicating that a higher amount
of the circulating VWF was in an active, platelet-binding conformation (Fig 3D).
ADAMTS13 functions as a natural regulator that de-activates the VWF by proteolysis [30]
and can be consumed by high levels of circulating VWF [12]. ADAMTS13 activity levels were
decreased in leptospirosis patients and were lowest in bleeders (Fig 3E). Three patients in the
bleeders group had ADAMTS13 activity level lower than 10%. An ADAMTS13 activity below
50% was found in 11 (73%) patients in the bleeders group and only in three (25%) patients in
the non-bleeders group. In the leptospirosis group as a whole, platelet-VWF binding correlated
positively with the VWF activation factor (R = 0.62; P = 0.001; Fig 3F). Additionally, whereas
ADAMTS13 activity did not correlate with VWF activation factor, it had an inverse correlation
(R = -0.65; P = 0.0009) with plasma VWF levels, suggesting consumption of ADAMTS13 by
VWF (data for correlation between ADAMTS13 and plasma VWF shown in Fig 3F). These
correlations were consistent across the bleeders and non-bleeders group, as shown in S3A and
S3B Fig.
Additional analyses of the MAT-positive and MAT-negative subgroups are presented in S4
Fig while data on follow-up measurements on day 4 are presented in S5 Fig.
Platelet-vWF binding correlates with thrombocytopenia
Next, we checked associations between parameters to explore possible mechanisms underlying
the leptospirosis-associated thrombocytopenia and platelet dysfunction (Fig 4). First, there
was a strong inverse correlation of platelet count with platelet-VWF binding and to a lesser
extent with the platelet membrane expression of P-selectin (Fig 4A and 4B, day 4 data pre-
sented in S5 Fig). In contrast, plasma levels of the coagulation activation marker TAT complex
did not correlate with platelet numbers (Fig 4C). Next, we explored whether platelet-VWF
binding inhibited the platelet αIIbβ3 signaling pathway, as recently reported for von Willebrand
disease type 2B [15]. However, in contrast to our hypothesis, platelet-VWF binding correlated
positively with platelet-fibrinogen binding in unstimulated samples (Fig 4D; Spearman
R = 0.42; P = 0.02), and there was a trend for a positive correlation with high dose TRAP- and
ADP-stimulated fibrinogen binding (R = 0.33; P = 0.19 for ADP and R = 0.30; P = 0.13 for
TRAP).
Another possible cause of platelet dysfunction is uremia due to the presence of uremic tox-
ins in the blood [31]. Although we did observe a trend for higher urea levels in bleeders com-
pared to non-bleeders (P = 0.06), we did not find any associations between ureum levels with
either P-selectin at baseline (Spearman R = -0.17, P = 0.36) or upon stimulation with ADP (R
= -0.16, P = 0.43) or TRAP (R = -0.11, P = 0.58)
Discussion
Our study reveals four important findings. First, platelet activation is a feature of severe, proba-
ble leptospirosis, especially in cases with bleeding manifestations. Second, bleeding complica-
tions are predominantly associated with platelet dysfunction rather than absolute platelet
count. Third, circulating platelets in probable leptospirosis patients bind more VWF and this
has a strong negative association with platelet number, in contrast with the plasma coagulation
marker TAT complexes. Fourth, platelet-VWF binding did not diminish with agonist-induced
platelet-fibrinogen binding (Fig 4D), disproving our hypothesis that increased platelet-VWF
binding underlies the inhibition of the platelet αIIbβ3 signaling pathway, as recently reported
for von Willebrand disease type 2B [15].
Platelet dysfunction in patients with probable leptospirosis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005915 September 21, 2017 10 / 18
To the best of our knowledge, this is the first study measuring platelet activation and reac-
tivity in patients with probable leptospirosis. Platelet function studies are logistically challeng-
ing, as blood samples need to be processed without delay. In conditions with
thrombocytopenia, aggregometry is also less reliable and flow cytometry-based assays are pre-
ferred [8]. The findings of our study are consistent with those from an experimental leptospi-
rosis guinea pig model in which platelets were found in hepatic sinusoids [32] and in which
thrombocytopenia was not related to disseminated intravascular coagulation. Another animal
study, using a virulent serovar of Leptospira interrogans in gerbils, reported increased levels of
platelet-activating factor acetylhydrolase (PAF-AH), which might contribute to inhibition of
platelet activation [33]. Our observation that platelet function, rather than the absolute platelet
count, determined the bleeding risk is consistent with increasing evidence from patients with
Fig 4. Platelet count and platelet-VWF binding correlates. (A-C) Spearman correlation of platelet count with platelet-VWF binding, platelet P-
selectin expression and thrombin anti-thrombin complex. (D) Spearman correlation of platelet-VWF binding and platelet-fibrinogen binding in
unstimulated sample (left panel) and upon ADP (125 μM) and TRAP (625 μM) stimulation (middle and right panel). Data for leptospirosis patients with
and without bleeding are shown.
https://doi.org/10.1371/journal.pntd.0005915.g004
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immune thrombocytopenic purpura (ITP) that has identified platelet function as an important
determinant of bleeding risk [34–36].
Some of the platelet parameters did not show statistically significant differences between
the bleeding and non-bleeding groups. For example, platelet reactivity to ADP stimulation was
lower in those with bleeding, but this did not reach statistical significance (Fig 1A). Except for
the small sample size, lack of statistical difference may also reflect the fact that factors other
than platelet dysfunction may contribute to bleeding, including inflammation, endotheliopa-
thy and coagulopathy.
High plasma VWF levels, together with elevations in other endothelial cell activation mark-
ers, were recently reported in patients with leptospirosis [37]. Our findings add to this by
showing that the circulating VWF is in an active, GPIbα-binding conformation, and that cir-
culating platelets indeed have more VWF on their surface. Most VWF is derived from endo-
thelial cells. However, platelets also contain VWF in their granules [38] and to what extent this
contributes to the increased VWF binding on the platelet membrane is unknown. We also
found a concurrent decrease in ADAMTS13 activity levels. This enzyme regulates the multi-
meric size and function of VWF through the cleavage of VWF within the A2 domain [39]. A
severe reduction in ADAMTS13 activity as a result of auto-antibodies is a hallmark of the rare
disease thrombotic thrombocytopenic purpura (TTP) [40]. Cases of leptospirosis-associated
TTP have also been described, including that with severely reduced ADAMTS13 activity [41,
42]. Infections may lead to significant reductions in ADAMTS13 as a result of different mecha-
nisms, as recently reviewed by Schwameis [43]. Multiple studies have shown that conditions
with increased VWF release are associated with secondary ADAMTS13 consumption, such as
in severe systemic infections [44] and after desmopressin-induced VWF release [45]. Inhibi-
tion of ADAMTS13 activity can also occur due to inflammation-induced IL-6 release [46] or
proteolytic cleavage of ADAMTS13 by neutrophils [47]. And lastly, competition of
ADAMTS13 with thrombospondin-1 for the interaction with the VWF-A3 domain may slow
the proteolysis of ultra large (UL)-VWF multimers [43].
The mechanisms underlying the observed platelet activation and platelet dysfunction in our
study population remain to be elucidated. It is unknown whether pathogenic Leptospira inter-
rogans strains are able to directly interact with and activate platelets. Leptospiral lipopolysac-
charide (LPS) was shown to be a ligand of Toll-like receptor (TLR)-2 and TLR4 in human
whole blood and in mice [48, 49]. Platelets harbor both TLRs and the ligation of TLR-2 espe-
cially leads to a strong thrombotic platelet activating response [50]. Alternatively, increased
platelet-VWF binding may activate platelets [51]. In patients with von Willebrand disease type
2B (VWD type 2B), a disease characterized by gain-of-function mutations in VWF that
enhance its spontaneous binding to the platelet GPIbα, increased platelet-VWF binding is
associated with thrombocytopathy due to inhibition of αIIbβ3 activation [15]. We also hypothe-
sized that this might underlie thrombocytopathy in leptospirosis, but this is unlikely with our
finding of a positive correlation of platelet-VWF binding with fibrinogen binding to the acti-
vated αIIbβ3 receptor in response to platelet agonists (Fig 4D). Another explanation might be
that excessive platelet activation is responsible for less reactive and functional platelets. The
exposure of platelets to inducers of platelet activation such as thrombin [52] or VWF [53] may
lead to a partial release or incomplete degranulation of platelets, leading to impairment of their
hemostatic effectiveness [16]. The combination of a higher platelet activation status of circulat-
ing platelets in the bleeding leptospirosis patients with reduced reactivity to ex vivo activation
(Fig 1A) would certainly fit this hypothesis. A similar platelet phenotype was previously found
in patients with other hemorrhagic infectious diseases, such as severe dengue [17]. In hantavi-
rus-infected patients, platelet reactivity to agonist stimulation was significantly lower during
disease compared to follow-up [54]. Impaired platelet dysfunction appears specific for these
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‘hemorrhagic’ diseases and does not appear to result from more general factors such as inflam-
mation, as most other infections increase platelet reactivity. For example, we found increased
platelet reactivity using similar assays as employed in the current study in patients with sepsis
due to common Gram-positive pathogens [55], pigs with pneumococcal bacteremia [56] and
HIV-infected individuals on antiretroviral therapy [22]. In addition, we did not find systemic
platelet activation in volunteers participating in a controlled human malaria infection, despite
developing thrombocytopenia, which may explain why malaria is rarely complicated by bleed-
ing [57].
There was a strong inverse correlation of VWF-platelet binding with platelet number, sug-
gesting that VWF bound to the platelet membrane is involved in platelet clearance. Increased
platelet-VWF interaction in VWD type 2B results in increased platelet clearance by the liver
[58]. How the VWF-platelet complexes are being cleared remains to be determined. Evidence
suggests that glycans on GPIbα are critical in mediating platelet clearance via receptors con-
taining carbohydrate-binding domains on the macrophage αMβ2 integrin and the hepatic
Ashwell-Morell receptor [29, 59, 60]. One plausible mechanistic explanation is that the
increased platelet-VWF binding results in a structural unfolding of the GPIbα extracellular
domain and triggers signaling into the platelet, desialylation of the platelet surface and platelet
clearance [61].
The limitations of our study include the small number of patients tested positive with the
MAT and the fact that patients were included solely based on a positive result of a rapid IgM
lateral flow test combined with clinical manifestations consistent with leptospirosis, classifying
the cases as probable leptospirosis. Individuals in the control group were all IgM lateral flow
negative. The diagnosis of leptospirosis is challenging with current gold standard tests such as
the MAT being imperfect and technically demanding [19]. At the time of the study, other diag-
nostic tests such as an IgM ELISA or PCR were not available in our setting. It is also uncertain
whether PCR would have yielded a high sensitivity in our cohort as most cases were enrolled
only in the second week of illness when the PCR is frequently already negative. The low num-
ber of patients with a positive MAT might be explained by the fact that the MAT also has lim-
ited sensitivity [19]. MAT gives a large number of false negative results in the early course of
infection, as IgM antibodies detectable by MAT only appear after day 8 of illness and reach the
peak by week 4 [62, 63]. MAT requires collection of paired sera at appropriate time intervals
for the most accurate interpretation of results. Therefore, although it is of high value for epide-
miological purposes, its value in the acute clinical setting is limited [64]. Many cases in our
study could thus only be classified as probable leptospirosis. Subgroup analysis, however, did
not show any differences in platelet parameters between those with a positive or negative result
of the MAT. In addition, even though leptospirosis is a common cause of undifferentiated
fever in Semarang, Indonesia, where our study was performed, we cannot exclude other co-
infections, such as murine typhus [65].
In conclusion, we found that platelet activation and platelet dysfunction are features of
patients with probable leptospirosis diagnosis that are associated with the severity of bleeding
events. Circulating platelets also bind more with VWF, and although this does not explain the
observed platelet dysfunction, it may play a role in platelet activation and clearance. Bleeding
is a serious, life-threatening complication of leptospirosis and our findings warrant further
study on the clinical utility of platelet function tests, as it is thrombocytopathy rather than
thrombocytopenia that is associated with the severity of bleeding events. In severe bleeding,
platelet transfusion may temporarily reverse platelet dysfunction. In addition, given the pre-
sumed role of excessive VWF-platelet interaction in thrombocytopenia in severe leptospirosis,
novel therapies aimed at preventing this interaction, including recombinant ADAMTS13 [66],
might also have some therapeutic value. This needs to be addressed in future studies.
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S1 Fig. Correlations between bleeding scale and ADP-induced (125 μM) P-selectin expres-
sion (A) and platelet-fibrinogen binding (B). Shown are the Spearman correlation coefficients.
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S2 Fig. Platelet activation and reactivity upon follow-up at day four. (A) Platelet-fibrinogen
binding and the platelet membrane expression of P-selectin (depicted as median fluorescence
intensity (MFI) in arbitrary units) in unstimulated samples and after stimulation with two con-
centrations of the platelet agonists, thrombin receptor activating peptide (TRAP) and adeno-
sine diphosphate (ADP), in leptospirosis patients with bleeding (bleeders, n = 15) and without
bleeding (non-bleeders, n = 18) and in healthy controls (n = 25).  P<0.05, P<0.005. (B)
Plasma concentration of soluble P-selectin. Data depicted are medians with IQR. Data of
patients were from day 4, while data from healthy controls were from day 1.
(PDF)
S3 Fig. Relationship between platelet-von Willebrand factor (VWF) binding and VWF
activation factor as well as ADAMTS13 and plasma VWF levels. (A) Spearman correlation
coefficient of VWF activation factor and platelet-VWF binding in the bleeders and non-bleed-
ers. (B) Spearman correlation coefficient of plasma VWF and ADAMTS13 activity of bleeders
and non-bleeders.
(PDF)
S4 Fig. Platelet-von Willebrand factor (VWF) binding in patient groups based on micro-
scopic agglutination test (MAT) results. Platelet-VWF binding (depicted as median fluores-
cence intensity (MFI) in arbitrary units) in unstimulated samples (A) and after ex vivo
stimulation with two concentrations of ristocetin (B). P<0.005.
(PDF)
S5 Fig. Platelet-von Willebrand factor (VWF) binding, plasma VWF, VWF activation fac-
tor and platelet count correlates upon follow-up at day 4. (A) Platelet-VWF binding
(depicted as median fluorescence intensity (MFI) in arbitrary units) in unstimulated samples
and after ex vivo stimulation with two concentrations of ristocetin. (B-C) Plasma concentra-
tions of VWF and VWF activation factor. (D) Spearman correlation coefficient of platelet
count and platelet-VWF binding as well as platelet P-selectin expression. Data are shown as
medians with IQR. Data from patients were from day 4, while data from healthy controls were
from day 1.
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